Bio-3D printed organs as drug testing tools

Kenichi Arai*, Koichi Nakayama

*この論文の責任著者

研究成果: 書籍の章/レポート/会議録査読

1 被引用数 (Scopus)

抄録

Evaluations of side effects and therapeutic efficacy are key steps in drug development. This process is time-consuming and costly and is often discontinued owing to differences in the drug response between animal models and humans, necessitating alternative approaches to animal models. One promising alternative for evaluations of therapeutic efficacy and adverse reactions is human induced pluripotent stem cells (iPS cells). Human iPS cells can differentiate into various cell types. Furthermore, using iPS cells derived from patients, useful human disease models can be established for the development of drugs against a wide range of diseases. Although cells are cultured on a culture dish, spheroids and organoids, which are aggregates of cells with tissue-specific functions, develop to mimic the three-dimensional (3D) cell environment. Bio-3D printing has been developed to generate scaffold-free constructs by using spheroids according to a desired design. The combination of organoids and bio-3D printing is expected to enable the fabrication of constructs with tissue-specific functions for drug testing. In this chapter, we discuss the current status of drug development and tissue engineering techniques as well as the fabrication of spheroids or organoids and applications for drug evaluation. Finally, we discuss the existing challenges and future prospects.

本文言語英語
ホスト出版物のタイトルKenzan Method for Scaffold-Free Biofabrication
出版社Springer International Publishing
ページ149-164
ページ数16
ISBN(電子版)9783030586881
ISBN(印刷版)9783030586874
DOI
出版ステータス出版済み - 2021/01/22

ASJC Scopus 主題領域

  • 工学一般
  • 生化学、遺伝学、分子生物学一般
  • 医学一般
  • 健康専門職一般

フィンガープリント

「Bio-3D printed organs as drug testing tools」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル